SMARCA4‑deficient uterine adnexal tumor with ascites: A case report and literature review

Li,Xiu-Feng; Zhang,Yu-Ping; Wei,Li-Li; Wang,Zheng-Jiang; Yang,Mai-Qing

doi:10.3892/ol.2024.14490

SMARCA4‑deficient uterine adnexal tumor with ascites: A case report and literature review

Authors:
- Xiu-Feng Li
- Yu-Ping Zhang
- Li-Li Wei
- Zheng-Jiang Wang
- Mai-Qing Yang
View Affiliations

Affiliations: Department of Pathology, Weifang People's Hospital (First Affiliated Hospital of Shandong Second Medical University), Weifang, Shandong 261041, P.R. China, Department of Pathology, Changyi Maternal and Child Health Hospital, Changyi, Shandong 261300, P.R. China, Department of Pathology, Weifang People's Hospital (First Affiliated Hospital of Shandong Second Medical University), Weifang, Shandong 261041, P.R. China
Published online on: June 5, 2024 https://doi.org/10.3892/ol.2024.14490
Article Number: 357
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SWI/SNF‑related matrix‑associated actin‑dependent regulator of chromatin subfamily A member 4 (SMARCA4)‑deficient tumors are rare and highly aggressive tumors characterized by a loss of SMARCA4 expression, and SMARCA4‑deficient tumors in the adnexal area of the uterus are particularly rare. The present study describes the case of a 64‑year‑old woman who was admitted to Weifang People's Hospital (Weifang, China) with abdominal distension, and was observed to have a mass with ascites in the adnexal area of the uterus. Based on clinical, imaging and pathological findings, the patient was diagnosed with a SMARCA4‑deficient adnexal tumor with ascites. Biopsy of the left and right adnexal lesions was performed, and the patient was administered chemotherapy. After one cycle of bevacizumab, sindilizumab and carboplatin, no further treatment was administered. After biopsy and chemotherapy, the abdominal distension was alleviated and the general condition of the patient was satisfactory. The patient was followed up and died 3 months after treatment. Notably, it is important to avoid misdiagnosing this tumor as other types of adnexal uterine tumors, and morphological and immunohistochemical features may be useful for diagnosing primary SMARCA4‑deficient tumors in the adnexal area of the uterus.

View Figures

View References

1	Peng L, Li J, Wu J, Xu B, Wang Z, Giamas G, Stebbing J and Yu Z: A Pan-Cancer Analysis of SMARCA4 alterations in human cancers. Front Immunol. 12:7625982021. View Article : Google Scholar : PubMed/NCBI
2	Kakkar A, Ashraf SF, Rathor A, Adhya AK, Mani S, Sikka K and Jain D: SMARCA4/BRG1-Deficient Sinonasal Carcinoma. Arch Pathol Lab Med. 146:1122–1130. 2022. View Article : Google Scholar : PubMed/NCBI
3	Nambirajan A, Singh V, Bhardwaj N, Mittal S, Kumar S and Jain D: SMARCA4/BRG1-Deficient non-small cell lung carcinomas: A case series and review of the literature. Arch Pathol Lab Med. 145:90–98. 2021. View Article : Google Scholar : PubMed/NCBI
4	Ota T, Ishikawa T, Yasuda R, Yasuda T, Okayama T, Inoue K, Dohi O, Yoshida N, Kamada K, Uchiyama K, et al: The first case of SMARCA4-deficient sarcoma of stomach. Clin J Gastroenterol. 15:531–536. 2022. View Article : Google Scholar : PubMed/NCBI
5	Duan H, Gao W, Wang L, Cao F and Teng L: Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: A case report and literature review. Diagn Pathol. 16:302021. View Article : Google Scholar : PubMed/NCBI
6	Huang R, Chen L, Pan C and Fang X: SMARCA4-deficient dedifferentiated endometrioid carcinoma: A case report. Asian J Surg. 46:5484–5485. 2023. View Article : Google Scholar : PubMed/NCBI
7	Michel BC, D'Avino AR, Cassel SH, Mashtalir N, McKenzie ZM, McBride MJ, Valencia AM, Zhou Q, Bocker M, Soares LMM, et al: A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. Nat Cell Biol. 20:1410–1420. 2018. View Article : Google Scholar : PubMed/NCBI
8	Kim SY, Shen Q, Son K, Kim HS, Yang HD, Na MJ, Shin E, Yu S, Kang K, You JS, et al: SMARCA4 oncogenic potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in liver cancer. Oncogene. 40:4652–4662. 2021. View Article : Google Scholar : PubMed/NCBI
9	Guerrero-Martínez JA and Reyes JC: High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer. Sci Rep. 8:20432018. View Article : Google Scholar : PubMed/NCBI
10	Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, Grynspan D, Saloustros E, Nadaf J, Rivera B, et al: Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 46:438–443. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kolin DL, Quick CM, Dong F, Fletcher CDM, Stewart CJR, Soma A, Hornick JL, Nucci MR and Howitt BE: SMARCA4-deficient uterine sarcoma and undifferentiated endometrial carcinoma are distinct clinicopathologic entities. Am J Surg Pathol. 44:263–270. 2020. View Article : Google Scholar : PubMed/NCBI
12	Karanian-Philippe M, Velasco V, Longy M, Floquet A, Arnould L, Coindre JM, Le Naoures-Méar C, Averous G, Guyon F, MacGrogan G and Croce S: SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): A comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas. Am J Surg Pathol. 39:1197–1205. 2015. View Article : Google Scholar : PubMed/NCBI
13	Lin DI, Allen JM, Hecht JL, Killian JK, Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH, et al: SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. Mod Pathol. 32:1675–1687. 2019. View Article : Google Scholar : PubMed/NCBI
14	Azzalini E, Stanta G, Canzonieri V and Bonin S: Overview of tumor heterogeneity in high-grade serous ovarian cancers. Int J Mol Sci. 24:150772023. View Article : Google Scholar : PubMed/NCBI
15	Brambs CE, Höhn AK, Klagges S, Gläser A, Taubenheim S, Dornhöfer N, Einenkel J, Hiller GGR and Horn LC: Clinico-pathologic characteristics and prognostic factors of ovarian carcinoma with different histologic subtypes-A benchmark analysis of 482 cases. Pathol Res Pract. 233:1538592022. View Article : Google Scholar : PubMed/NCBI
16	Connor YD, Miao D, Lin DI, Hayne C, Howitt BE, Dalrymple JL, DeLeonardis KR, Hacker MR, Esselen KM and Shea M: Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. Gynecol Oncol. 157:106–114. 2020. View Article : Google Scholar : PubMed/NCBI
17	Lu B and Shi H: An in-depth look at small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): Clinical implications from recent molecular findings. J Cancer. 10:223–237. 2019. View Article : Google Scholar : PubMed/NCBI
18	Gao J, Fan R, Chen D, Hou J, Chen H and Lu M: Pathological characteristics and immune microenvironment of SMARCA4-deficient undifferentiated uterine sarcoma. Diagn Pathol. 18:622023. View Article : Google Scholar : PubMed/NCBI
19	Witkowski L, Goudie C, Ramos P, Boshari T, Brunet JS, Karnezis AN, Longy M, Knost JA, Saloustros E, McCluggage WG, et al: The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecol Oncol. 141:454–460. 2016. View Article : Google Scholar : PubMed/NCBI
20	Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y and Ohe Y: Efficacy of immune checkpoint inhibitors in SMARCA4-Deficient thoracic tumor. Clin Lung Cancer. 23:386–392. 2022. View Article : Google Scholar : PubMed/NCBI
21	Bhat V, Koneru M, Knapp K, Joneja U, Morrison J and Hong YK: Identification and treatment of SMARCA4 deficient poorly differentiated gastric carcinoma. Am Surg. 89:4987–4989. 2023. View Article : Google Scholar : PubMed/NCBI
22	Yang P, Xiong F, Lin Y, Liang P and Tang C: Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: A case report. Transl Cancer Res. 12:1041–1048. 2023. View Article : Google Scholar : PubMed/NCBI
23	Kunimasa K, Okami J, Takenaka S, Honma K, Kukita Y, Nagata S, Kawamura T, Inoue T, Tamiya M, Kuhara H, et al: Conversion surgery for advanced thoracic SMARCA4-Deficient undifferentiated tumor with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin treatment: A case report. JTO Clin Res Rep. 2:1002352021.PubMed/NCBI
24	Kurokawa M, Shimizuguchi T, Ito K, Takao M, Motoi T, Taguchi A, Yasugi T and Karasawa K: Notable Response of SMARCA4-Deficient undifferentiated uterine sarcoma to palliative radiation therapy. Adv Radiat Oncol. 6:1007282021. View Article : Google Scholar : PubMed/NCBI
25	Romero OA, Vilarrubi A, Alburquerque-Bejar JJ, Gomez A, Andrades A, Trastulli D, Pros E, Setien F, Verdura S, Farré L, et al: SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nat Commun. 12:43192021. View Article : Google Scholar : PubMed/NCBI
26	Qian B, Leng W, Yan Z, Lu J, Chen S, Yi H and Jiang Z: Clinical Benefit With PARP inhibitor for pathogenic germline FANCA-Mutated relapsed epithelial ovarian cancer: A case report. Front Oncol. 12:7785452022. View Article : Google Scholar : PubMed/NCBI
27	Liang X, Gao X, Wang F, Li S, Zhou Y, Guo P, Meng Y and Lu T: Clinical characteristics and prognostic analysis of SMARCA4-deficient non-small cell lung cancer. Cancer Med. 12:14171–14182. 2023. View Article : Google Scholar : PubMed/NCBI